Diffusion Pharmaceuticals Inc. (DFFN)

NASDAQ: DFFN · IEX Real-Time Price · USD
6.73
+0.15 (2.28%)
Feb 1, 2023, 11:29 AM EST - Market open
2.28%
Market Cap 13.71M
Revenue (ttm) n/a
Net Income (ttm) -14.99M
Shares Out 2.04M
EPS (ttm) -7.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,355
Open 6.58
Previous Close 6.58
Day's Range 6.58 - 6.96
52-Week Range 4.64 - 20.00
Beta 1.74
Analysts Buy
Price Target 25.25 (+275.19%)
Earnings Date Mar 20, 2023

About DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 16
Stock Exchange NASDAQ
Ticker Symbol DFFN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for DFFN stock is "Buy." The 12-month stock price forecast is $25.25, which is an increase of 275.19% from the latest price.

Price Target
$25.25
(275.19% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting

1 month ago - GlobeNewsWire

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci's History of Stockholder Value Destruction and Self-Dealing

CHARLOTTESVILLE, Va., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may en...

2 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may en...

2 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process

2 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas wher...

3 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

•  Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022 •  Reported Positive Effects in TSC Altitude Trial •  Ended Quarter with $28.5 million in Cash, Cash Equiv...

6 months ago - GlobeNewsWire

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

CHARLOTTESVILLE, Va., July 26, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies to enhance ...

6 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the b...

7 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilitie...

9 months ago - GlobeNewsWire

Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance...

9 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance...

9 months ago - GlobeNewsWire

5 Stocks Halted In Tuesday's Session

A circuit breaker is an automatic, temporary trading halt on specific securities when the underlying stock is experiencing times of high volatility. It is a measure to help restore and bring order to ...

Other symbols: LGHLSBFMSEV
10 months ago - Benzinga

Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) will effect a 1-for-50 reverse stock split of its common stock.  The reverse stock split is expected to become effective and commence trading on a post-spl...

10 months ago - Benzinga

Why Diffusion Pharmaceuticals Shares Are Falling

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares are trading lower by 20.83% at $0.21 after the company announced a 1-for-50 reverse stock split. Diffusion Pharmaceuticals says the reverse stock sp...

10 months ago - Benzinga

Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022 Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022

10 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

Topline data expected within two months

10 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders

• Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T. • No Change to Meeting Location, Record Date, or Proposals to Be Voted Upon

10 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., March 21, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapie...

11 months ago - GlobeNewsWire

Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts

New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia

1 year ago - GlobeNewsWire

Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P.

CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhan...

1 year ago - GlobeNewsWire

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

Third of Three TSC Oxygenation Trials Third of Three TSC Oxygenation Trials

1 year ago - GlobeNewsWire

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523

Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer

1 year ago - GlobeNewsWire

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial

Second of Three TSC Oxygenation Trials Second of Three TSC Oxygenation Trials

1 year ago - GlobeNewsWire

Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhanc...

1 year ago - GlobeNewsWire

Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference

CHARLOTTESVILLE, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies...

1 year ago - GlobeNewsWire